Showing results (1-10 of 26) with videos related to
Sort By:
Pageof 3
Diabetes Technology & Therapeutics|February 1, 2026
Overcoming Therapeutic Inertia with Inhaled Insulin TherapyThomas C Blevins, Steve V EdelmanDiabetes Technology & Therapeutics|February 1, 2026
Dosing Afrezza: It's Not that ComplicatedSteve V Edelman, Thomas C Blevins, Christopher G Parkin, et al.The Journal of Family Practice|October 10, 2017
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor AgonistsSteve V EdelmanJournal of Diabetes Science and Technology|March 24, 2010
Professional continuous glucose monitoring in clinical practice 2010Thomas C BlevinsPostgraduate Medicine|November 30, 2016
Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitusThomas C Blevins, Azeez FarookiDiabetes Care|April 19, 2014
AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetesSteve V Edelman, Rong Liu, Jennal Johnson, et al.The Diabetes Educator|December 14, 2018
Reference Guide for Integrating Continuous Glucose Monitoring Into Clinical PracticeDavida F Kruger, Steve V Edelman, Deborah A Hinnen, et al.Diabetes, Obesity & Metabolism|May 29, 2025
Risk of new-onset type 1 diabetes in individuals with celiac disease and thyroid disease-An observational studySteve V Edelman, Daniel Agardh, Nancy Cui, et al.Diabetes, Obesity & Metabolism|April 16, 2018
Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III studyThomas C Blevins, Abhijit Barve, Bin Sun, et al.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetesKenneth S Hershon, Thomas C Blevins, Christy A Mayo, et al.Pageof 3